Argos Therapeutics, Inc. (ARGS) Reaches $1.42 52-Week Low; MINTH GROUP LTD (MNTHF) Shorts Lowered By 4.93%

February 14, 2018 - By Dolores Ford

MINTH GROUP LTD (OTCMKTS:MNTHF) had a decrease of 4.93% in short interest. MNTHF’s SI was 1.41 million shares in February as released by FINRA. Its down 4.93% from 1.49 million shares previously. With 100 avg volume, 14130 days are for MINTH GROUP LTD (OTCMKTS:MNTHF)’s short sellers to cover MNTHF’s short positions. It closed at $5.89 lastly. It is down 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Argos Therapeutics, Inc. (NASDAQ:ARGS) hit a new 52-week low and has $1.33 target or 6.00% below today’s $1.42 share price. The 6 months bearish chart indicates high risk for the $8.72 million company. The 1-year low was reported on Feb, 14 by Barchart.com. If the $1.33 price target is reached, the company will be worth $522,960 less. The stock decreased 4.05% or $0.06 during the last trading session, reaching $1.42. About 86,764 shares traded. Argos Therapeutics, Inc. (NASDAQ:ARGS) has declined 92.57% since February 14, 2017 and is downtrending. It has underperformed by 109.27% the S&P500.

Minth Group Limited, an investment holding company, designs, develops, makes, processes, and sells automobile body parts and molds of passenger cars in the PeopleÂ’s Republic of China and internationally. The company has market cap of $6.10 billion. The Company’s products include windshield moldings, inner beltline moldings, door frame opening moldings, sill plates, fender trims, run channel moldings, outer beltline moldings, upper reveal moldings, and roof ditch moldings. It has a 21.65 P/E ratio. The firm also offers front delta inner covers, rear quarter windows, door handle and grille assemblies, rear decklids, mudguard sets, logo emblems, wheel covers, molding ASM-R, and body side moldings; and body structural parts comprising rear and front door sash products, B-pillar covers, and guide rails.

Investors sentiment increased to 0.63 in Q3 2017. Its up 0.09, from 0.54 in 2017Q2. It improved, as 13 investors sold Argos Therapeutics, Inc. shares while 6 reduced holdings. 8 funds opened positions while 4 raised stakes. 2.64 million shares or 38.27% more from 1.91 million shares in 2017Q2 were reported. 119,515 are held by Keybank National Association Oh. Vanguard holds 851,235 shares. Guggenheim Cap Ltd Co has 27,984 shares. Millennium Mngmt Ltd Com stated it has 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Bnp Paribas Arbitrage accumulated 0% or 4 shares. Blackrock Incorporated has 7,054 shares for 0% of their portfolio. State Street reported 11,900 shares stake. Hightower Advisors Ltd Liability Company has invested 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). California Public Employees Retirement Sys accumulated 94,800 shares or 0% of the stock. Stifel Financial reported 0% stake. Meeder Asset Incorporated accumulated 11,950 shares. Royal Bank Of Canada holds 0% of its portfolio in Argos Therapeutics, Inc. (NASDAQ:ARGS) for 1,651 shares. Northern Tru Corp reported 0% of its portfolio in Argos Therapeutics, Inc. (NASDAQ:ARGS). Deutsche State Bank Ag holds 0% or 36 shares. Bancorp Of Mellon holds 74,379 shares.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $8.72 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>